Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction.

Parry TJ, Ganguly A, Troy EL, Luis Guerrero J, Iaci JF, Srinivas M, Vecchione AM, Button DC, Hackett CS, Zolty R, Sawyer DB, Caggiano AO.

Eur J Pharmacol. 2017 Feb 5;796:76-89. doi: 10.1016/j.ejphar.2016.12.024. Epub 2016 Dec 16.

2.

The genetics of splicing in neuroblastoma.

Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA.

Cancer Discov. 2015 Apr;5(4):380-95. doi: 10.1158/2159-8290.CD-14-0892. Epub 2015 Jan 30.

3.

Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan Q, Weiss WA.

Cell Rep. 2014 Nov 6;9(3):1034-46. doi: 10.1016/j.celrep.2014.09.046. Epub 2014 Oct 23.

4.

Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer.

Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM, Tapscott SJ.

Epigenetics. 2013 Dec;8(12):1254-60. doi: 10.4161/epi.26486. Epub 2013 Oct 9.

5.

Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics.

Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK, Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, James CD, Rowitch DH, Shuman MA, Jan YN, Jan LY.

Genes Dev. 2012 Aug 15;26(16):1780-96. doi: 10.1101/gad.193789.112. Epub 2012 Aug 1.

6.

Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA.

Cancer Cell. 2012 May 15;21(5):601-13. doi: 10.1016/j.ccr.2012.04.012.

7.

Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.

Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA.

Sci Transl Med. 2012 Jan 4;4(115):115ra3. doi: 10.1126/scitranslmed.3002977.

8.

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A.

Nat Med. 2010 Oct;16(10):1134-40. doi: 10.1038/nm.2227. Epub 2010 Sep 26.

9.

Pleiotropic role for MYCN in medulloblastoma.

Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L.

Genes Dev. 2010 May 15;24(10):1059-72. doi: 10.1101/gad.1907510.

10.

A translational end-run for a rare, genetically enigmatic tumor.

Hackett CS, Weiss WA.

Cancer Biol Ther. 2009 Dec;8(24):2396-7. Epub 2009 Dec 3. No abstract available.

PMID:
20009571
11.

Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.

Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, Weiss WA, Jenkins RB, Largaespada DA.

Cancer Res. 2009 Nov 1;69(21):8429-37. doi: 10.1158/0008-5472.CAN-09-1760. Epub 2009 Oct 20.

12.
13.

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.

Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA.

Cancer Res. 2007 Sep 1;67(17):7960-5.

14.

Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.

Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Hackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M.

Eur J Cancer. 2007 Jun;43(9):1467-75. Epub 2007 Apr 20.

15.

Structure-based prediction of insertion-site preferences of transposons into chromosomes.

Geurts AM, Hackett CS, Bell JB, Bergemann TL, Collier LS, Carlson CM, Largaespada DA, Hackett PB.

Nucleic Acids Res. 2006 May 22;34(9):2803-11. Print 2006.

16.

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ.

Clin Cancer Res. 2006 Feb 15;12(4):1373-82.

17.

Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.

Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA.

Cancer Res. 2003 Sep 1;63(17):5266-73.

18.

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

Treanor JJ, Betts RF, Smith GE, Anderson EL, Hackett CS, Wilkinson BE, Belshe RB, Powers DC.

J Infect Dis. 1996 Jun;173(6):1467-70.

PMID:
8648221
19.

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, Volvovitz F, Belshe RB, Treanor JJ.

J Infect Dis. 1995 Jun;171(6):1595-9.

PMID:
7769297
20.
21.

NADH binding to cytochrome b5 reductase blocks the acetylation of lysine 110.

Hackett CS, Novoa WB, Kensil CR, Strittmatter P.

J Biol Chem. 1988 Jun 5;263(16):7539-43.

22.

Bacterial synthesis of active rat stearyl-CoA desaturase lacking the 26-residue amino-terminal amino acid sequence.

Strittmatter P, Thiede MA, Hackett CS, Ozols J.

J Biol Chem. 1988 Feb 15;263(5):2532-5.

23.

Identification of the essential cysteine residue of NADH-cytochrome b5 reductase.

Hackett CS, Novoa WB, Ozols J, Strittmatter P.

J Biol Chem. 1986 Jul 25;261(21):9854-7.

24.
25.

Synthesis and degradation of nitrate reductase in Escherichia coli.

Hackett CS, MacGregor CH.

J Bacteriol. 1981 Apr;146(1):352-9.

Supplemental Content

Loading ...
Support Center